Arthur Gran, MD
Infectious Disease · Troy, NYNPI 1689945206
Payments from drug & device makers
Across 77 payments — averaging $39.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$868
- Astellas Pharma US Inc$540
- Merck$464
- Hydrofera LLC$354
- Insmed, Inc.$269
- Kerecis Limited$158
- plus $389 from 9 others
What the payments were for
- Food & beverage$2,68888%
- Education$35412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $868 |
| Astellas Pharma US Inc | 13 | $540 |
| Merck | 15 | $464 |
| Hydrofera LLC | 5 | $354 |
| Insmed, Inc. | 12 | $269 |
| Kerecis Limited | 1 | $158 |
| Paratek Pharmaceuticals, Inc. | 4 | $97 |
| Melinta Therapeutics, LLC | 4 | $74 |
| Ferring Pharmaceuticals Inc. | 2 | $60 |
| Shionogi Inc | 2 | $43 |
| Solventum Corporation | 1 | $33 |
| Theratechnologies Inc. | 1 | $29 |
| Viiv Healthcare Company | 1 | $27 |
| GSK | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$632
- DALVANCE$364
- HYDROFERA BLUE$292
- Kerecis GraftGuide$158
- EMBLAVEO$125
- AVYCAZ$125
- CRESEMBA$123
How this compares
$3,042 in reported general payments places this provider in the 75th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $109,394 |
| ErtapenemErtapenem Sodium | 37 | $26,176 |
| Daptomycin | 18 | $4,438 |
| CeftriaxoneCeftriaxone Sodium | 15 | $2,269 |
| Ethambutol Hcl | 25 | $938 |
| Cefazolin Sodium | 11 | $725 |
| Doxycycline Hyclate | 20 | $676 |
| Rifampin | 20 | $631 |
| Azithromycin | 23 | $559 |
| Minocycline Hcl | 20 | $475 |
| Cephalexin | 12 | $303 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Troy
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Stephen ThomasSyracuse$6.2M
- Edward WalshRochester$3.9M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Catherine SmallValhalla$2.7M
- Ann FalseyRochester$1.7M
- Barry ZingmanBronx$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.